Strides Pharma announces JV with Chinese firm to launch its products

The development comes in the backdrop of the recent regulatory developments in China which has enabled fast track approvals of differentiated high-quality generics approved in key regulated markets

Strides Pharma Science Limited has announced entry into Chinese market through a Joint Venture between its Singapore-based step down subsidiary Strides Pharma Global Pte (SPG) and Sun Moral International (HK) Limited, a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group Ltd (Sihuan), one of China’s leading pharmaceutical companies. 

China is the second-largest pharmaceutical market with a $137 billion market opportunity. Sihuan has a market share of 8.3 per cent in the cardio-cerebral vascular market and presence in other therapeutic areas.

“We look forward to strengthening the partnership in the near term to build a strong pharmaceutical franchise in China,” said Strides